 toxic immunomodulatori effect autolog bone marrow transplant hematolog malign autolog bone marrow transplant abmt advanc hematolog malign high relaps rate lymphokine-activ killer lak cell non-cross-resist therapeut modal relaps abmt time tumor burden minim high-dos chemoradiotherapi abmt patient suscept toxic immunolog respons vivo safeti toler immunomodulatori effect therapi abmt continu intraven infus patient day median abmt acut leukemia lymphoma multipl myeloma patient induct dose day patient nonescal mainten dose day patient mild fever nausea diarrhea and/or skin rash infus maximum toler induct dose dose-limit toxic hypotens thrombocytopenia toxic infus patient mainten postinfus lymphocytosi patient dose level dose percentag patient pbmc augment lysi daudi induct natur killer lak effector activ lak precursor activ patient dose level therapi regimen abmt immunomodulatori effect dose studi use lak cell abmt attempt relaps advanc hematolog malign